Review Article| Volume 41, ISSUE 1, P133-151, March 2021

Hemolytic Disease of the Fetus and Newborn

Historical and Current State
Published:December 22, 2020DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bourgeois L.
        Observations diverses sur la stérilité, perte de fruict, foecondité accouchements et maladies des femmes et enfants nouveaux naiz.
        Am J Obstet Gynecol. 1995; 173: 1893-1894
        • Santavy J.
        Hemolytic disease in the newborn - history and prevention in the world and the Czech republic.
        Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010; 154: 147-151
        • Diamond L.K.
        • Blackfan K.D.
        • Baty J.M.
        Erythroblastosis fetalis and its association with universal edema of the fetus, icterus gravis neonatorum and anemia of the newborn.
        J Pediatr. 1932; 1: 269-309
        • Darrow R.R.
        Icterus gravis (Erythroblastosis) neonatorum.
        Rhesus Haemolytic Disease. 1938; : 3-37
        • Fasano R.M.
        • Hendrickson J.E.
        • Luban N.L.C.
        • Burns M.C.
        Chapter 55: alloimmune hemolytic disease of the fetus and newborn.
        in: Kaushansky K. Lichtman M.A. Prchal J.T. Williams hematology. 9th edition. McGraw-Hill Medical, New York (NY)2010
        • Kantha S.S.
        The blood revolution initiated by the famous footnote of Karl Landsteiner's 1900 paper.
        Ceylon Med J. 1995; 40: 123-125
        • Landsteiner K.
        • Wiener A.S.
        An agglutinable factor in human blood recognized by immune sera for rhesus blood.
        Rhesus Haemolytic Disease. 1940; : 41-42
        • Stockman J.A.
        Overview of the state of the art of Rh disease: history, current clinical management, and recent progress.
        J Pediatr Hematol Oncol. 2001; 23: 554-562
        • Rosse W.F.
        Clinical Immunohematology: Basic Concepts in Clinical Applications.
        Blackwell Scientific Publications, Boston1990
        • Ballantyne J.W.
        Manual of antenatal pathology and hygiene: the fetus..
        JAMA. 1902; XXXIX: 783
        • Ballantyne J.W.
        The Diseases and Deformities of the Foetus.
        Oliver and Boyd, Edinburgh1885
        • Levine P.
        Serological Factors as Possible Causes in Spontaneous Abortions.
        in: Rhesus haemolytic disease. Springer, 1943
        • Levine P.
        • Katzin E.M.
        • Burnham L.
        Isoimmunization in pregnancy.
        J Am Med Assoc. 1941; 116: 825
        • Wegmann A.
        • Ghick R.
        The history of rhesus prophylaxis with anti-D.
        Eur J Pediatr. 1996; 155: 835-838
        • Stern K.
        • Davidsohn I.
        • Masaitis L.
        Experimental studies on Rh immunization.
        Am J Clin Pathol. 1956; 26: 833-843
        • Stern K.
        • Goodman H.S.
        • Berger M.
        Experimental isoimmunization to hemoantigens in man.
        Rhesus Haemolytic Disease. 1961; : 161-169
        • Finn R.
        • Clarke C.A.
        • Donohoe W.T.A.
        • et al.
        Experimental studies on the prevention of Rh haemolytic disease.
        BMJ. 1961; 1: 1486-1490
        • Freda V.J.
        • Gorman J.G.
        • Pollack W.
        Successful prevention of experimental Rh sensitization in man with an anti-Rh Gamma2-globulin antibody preparation: a preliminary report.
        Rhesus Haemolytic Disease. 1964; : 177-184
        • Freda V.
        • Gorman J.
        • Pollack W.
        Prevention of rhesus hæmolytic disease.
        Lancet. 1965; 286: 690
        • Schneider J.
        Die quantitative Bestimmung fetaler Erythrocyten im miitterlichen Kreislauf und deren beschleunigter Abbau durch Antik6rperseren.
        Geburtshilfe Frauenheilkd. 1963; 3: 562-568
        • Moise K.J.
        Hemolytic disease of the fetus and newborn.
        Clin Adv Hematol Oncol. 2013; 11: 664-666
      1. Dror Y, Chan AKC, Baker JM, et al, editors. Hematology avery's neonatology, pathophysiology, and management of the newborn. Wolters Kluwer: Philadelphia; 7th edition.

        • Kumpel B.M.
        On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.
        Transfusion. 2006; 46: 1652-1656
        • Zipursky A.
        • Israels L.G.
        The pathogenesis and prevention of Rh immunization.
        Rhesus Haemolytic Disease. 1967; : 253-266
      2. International society of blood transfusion.
        (Available at:) (Accessed August 31, 2020)
        • Dean L.
        Blood groups and red cell antigens [Internet].
        (Chapter 4, Hemolytic disease of the newborn) National Center for Biotechnology Information (US), Bethesda (MD)2005 (Available at:)
        • Ross M.E.
        • Waldron P.E.
        • Cashore W.J.
        • et al.
        Hemolytic disease of the fetus and newborn.
        in: de Alacon P.A. Werner E.J. Christensen R.D. Neonatal hematology: pathogenesis, diagnosis, and management of hematologic problems. 2nd edition. Cambridge University Press, Cambridge (United Kingdom)2013
        • Mitchell S.
        • James A.
        Severe late anemia of hemolytic disease of the newborn.
        Paediatr Child Health. 1999; 4: 201-203
        • Leung A.K.
        • Sauve R.S.
        Breastfeeding and breast milk jaundice.
        J R Soc Health. 1989; 109: 213-217
        • Gourley G.R.
        Bilirubin metabolism and kernicterus.
        Adv Pediatr. 1997; 44: 173-229
        • AU Vaughan JI.
        • Warwick R.
        • Letsky E.
        • et al.
        Erythropoietic suppression in fetal anemia because of Kell alloimmunization.
        Am J Obstet Gynecol. 1994; 171: 247
        • de Haas M.
        • Thurik F.F.
        • Koelewijn J.M.
        • et al.
        Haemolytic disease of the fetus and newborn.
        Vox Sang. 2015; 109: 99-113
        • Haider M.
        • Memon S.
        • Tariq F.
        • et al.
        Rhesus isoimmunization: late-onset hemolytic disease of the newborn without jaundice.
        Cureus. 2020; 12: e6559
        • Sandler S.G.
        • Chen L.N.
        • Flegel W.A.
        Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype.
        Br J Haematol. 2017; 179: 10-19
        • Rizzo C.
        • Castiglia L.
        • Arena E.
        • et al.
        Weak D and partial D: our experience in daily activity.
        Blood Transfus. 2012; 10: 235-236
        • Basu S.
        • Kaur R.
        • Kaur G.
        Hemolytic disease of the fetus and newborn: current trends and perspectives.
        Asian J Transfus Sci. 2011; 5: 3-7
        • Ree I.M.C.
        • Smits-Wintjens V.E.H.J.
        • van der Bom J.G.
        • et al.
        Neonatal management and outcome in alloimmune hemolytic disease.
        Expert Rev Hematol. 2017; 10: 607-616
        • Bowman J.M.
        RhD hemolytic disease of the newborn.
        N Engl J Med. 1998; 339: 1775-1777
        • Wallerstein H.
        Treatment of severe erythroblastosis by simultaneous removal and replacement of blood of the newborn.
        Science. 1946; 103: 583-584
        • Mourant A.
        • Kipec A.
        • Domaniewska-Sobezak K.
        The distribution of human blood groups and other polymorphisms.
        Oxford University Press, London (United Kingdom)1976
        • Murray N.A.
        • Roberts I.A.
        Haemolytic disease of the newborn.
        Arch Dis Child Fetal Neonatal Ed. 2007; 92: F83-F88
        • Jeon H.
        • Calhoun B.
        • Pothiawala M.
        • et al.
        Significant ABO hemolytic disease of the newborn in a group B infant with a group A2 mother.
        Immunohematology. 2000; 16: 105-108
        • McDonnell M.
        • Hannam S.
        • Devane S.
        Hydrops fetalis due to ABO incompatibility.
        Arch Dis Child Fetal Neonatal Ed. 1998; 78: F220-F221
        • Dean L.
        Blood groups and red cell antigens.
        National Center for Biotechnology Information (US), Bethesda (MD)2005 (Chapter 7, The Rh blood group) (Available at:)
        • Lopriore E.
        • Rath M.E.
        • Liley H.
        • et al.
        Improving the management and outcome in haemolytic disease of the foetus and newborn.
        Blood Transfus. 2013; 11: 484-486
        • Freda V.J.
        • Gorman J.G.
        • Pollack W.
        Successful prevention of experimental Rh sensitisation in man with an anti-Rh gamma-2-globulin preparation: a preliminary report.
        Transfusion. 1964; 4: 26-32
        • Weatherall D.J.
        Cyril Clarke and the prevention of rhesus haemolytic disease of the newborn.
        Br J Haematol. 2012; 157: 41-46
        • Bowman J.
        Thirty-five years of Rh prophylaxis.
        Transfusion. 2003; 43: 1661-1666
      3. Kedrion biopharma inc. RhoGam product label.
        (Available at:) (Accessed August 31, 2020)
        • Silver R.M.
        RhD immune globulin: over 50 years of remarkable progress.
        BJOG. 2016; 123 (Available at:): 1347
        • Kumpel B.M.
        • Elson C.J.
        Mechanism of anti-D-mediated immune suppression--a paradox awaiting resolution?.
        Trends Immunol. 2001; 22: 26-31
        • Hadley A.G.
        • Kumpel B.M.
        The role of Rh antibodies in haemolytic disease of the newborn.
        Baillieres Clin Haematol. 1993; 6: 423-444
        • Liumbruno G.M.
        • D’Alessandro A.
        • Rea F.
        • et al.
        The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation.
        Blood Transfus. 2010; 8: 8-16
        • Kumpel B.M.
        • Saldova R.
        • Koeleman C.A.M.
        • et al.
        Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.
        Sci Rep. 2020; 10: 1464
        • Harrison James
        Australian man with special blood type saves 2 million babies. The huffington post. March 24.
        (Available at:) (Accessed August 31, 2020)
        • Dean M.
        Wanted: Rh D negative donors. Australian prescriber.
        (Available at:) (Accessed August 31, 2020)
        • Crowther C.A.
        • Middleton P.
        Anti-D administration after childbirth for preventing Rhesus alloimmunisation.
        Cochrane Database Syst Rev. 1997;
        • Bowman J.M.
        The prevention of Rh immunization.
        Transfus Med Rev. 1988; 2: 129-150
        • Eklund J.
        • Hermann M.
        • Kjellman H.
        • et al.
        Turnover rate of anti-D IgG injected during pregnancy.
        BMJ. 1982; 284: 854-855
        • Lukacevic Krstic J.
        • Dajak S.
        • Bingulac-Popovic J.
        • et al.
        Anti-D antibodies in pregnant D variant antigen carriers initially typed as RhD.
        Transfus Med Hemother. 2016; 43: 419-424
        • Committee on Practice Bulletins-Obstetrics
        Practice bulletin No. 181: prevention of Rh D alloimmunization. 130. Obstetrics and Gynecology, New York (NY)2017: e57-e70 (1953)
        • Crowther C.A.
        • Middleton P.
        • McBain R.D.
        Anti-D administration in pregnancy for preventing Rhesus alloimmunisation.
        Cochrane Database Syst Rev. 2013; 2: CD000020
        • Klein H.
        • Anstee D.J.
        Haemolytic disease of the fetus and newborn.
        in: Mollison's blood transfusion in clinical medicine. 11th edition. Blackwell Publishing, Oxford (United Kingdom)2005: 496-545
        • Mahboob U.
        • Mazhar S.B.
        Role of Kleihauer test in Rhesus negative pregnancy.
        J Coll Physicians Surg Pak. 2006; 16: 120-123
        • Lindenburg I.
        • T M.
        • van Kamp I L.
        • et al.
        Intrauterine blood transfusion: current indications and associated risks.
        Fetal Diagn Ther. 2014; 36: 263-271
        • Bennardello F.
        • Coluzzi S.
        • Curciarello G.
        • et al.
        Italian society of transfusion medicine and immunohaematology (SIMTI) and Italian society of gynaecology and obstetrics (SIGO) working group. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn.
        Blood Transfus. 2015; 13: 109-134
        • Gottvall T.
        • Hildén J.O.
        Concentration of anti-D antibodies in Rh(D) alloimmunized pregnant women, as a predictor of anemia and/or hyperbilirubinemia in their newborn infants.
        Acta Obstet Gynecol Scand. 1997; 76: 733-738
        • Norwitz E.R.
        • Levy B.
        Noninvasive prenatal testing: the future is now.
        Rev Obstet Gynecol. 2013; 6: 48-62
        • Chandrasekharan S.
        • Minear M.A.
        • Hung A.
        • et al.
        Noninvasive prenatal testing goes global.
        Sci Transl Med. 2014; 6: 231fs15
        • Shourbagy S.E.
        • Elsakhawy M.
        Prediction of fetal anemia by middle cerebral artery Doppler.
        Middle East Fertil Soc J. 2012; 17: 275-282
        • Liley A.W.
        Intrauterine transfusion of foetus in haemolytic disease.
        Br Med J. 1963; 2: 1107-1109
        • Berkowitz R.L.
        • Hobbins J.C.
        Intrauterine transfusion utilizing ultrasound.
        Obstet Gynecol. 1981; 57: 33-36
        • Pasman S.A.
        • Claes L.
        • Lewi L.
        • et al.
        Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14 years experience in Leuven.
        Facts Views Vis Obgyn. 2015; 7: 129-136
        • Kanhai H.H.
        • Bennebroek Gravenhorst J.
        • Van Kamp I.L.
        • et al.
        Management of severe hemolytic disease with ultrasound-guided intravascular fetal transfusions.
        Vox Sang. 1990; 59: 180-184
        • Rodeck C.H.
        • Kemp J.R.
        • Holman C.A.
        • et al.
        Direct intravascular fetal blood transfusion by fetoscopy in severe Rhesus isoimmunisation.
        Lancet. 1981; 1: 625-627
        • Williams D.
        • Argaez C.
        Off-label use of intravenous immunoglobulin for hematological conditions: a review of clinical effectiveness. Ottawa (ON): Canadian agency for drugs and technologies in health.
        (Available at:) (Accessed August 31, 2020)
        • Mayer B.
        • Hinkson L.
        • Hillebrand W.
        • et al.
        Efficacy of antenatal intravenous immunoglobulin treatment in pregnancies at high risk due to alloimmunization to red blood cells.
        Transfus Med Hemother. 2018; 45: 429-436
        • Ambika S.
        • Wong G.
        • Salhotra A.
        • et al.
        Rekha parameswaran; early intravenous immunoglobulin (IVIG) therapy and non invasive fetal monitoring in rh alloimmunization (AI) and pregnancy.
        Blood. 2008; 112: 4069
        • Rock G.
        • Lafreniere I.
        • Chan L.
        • et al.
        Plasma exchange in the treatment of hemolytic disease of the newborn.
        Transfusion. 1981; 21: 546-551
        • Maki Y.
        • Ushijima J.
        • Furukawa S.
        • Inagaki H.
        • et al.
        Plasmapheresis for the treatment of anti-M alloimmunization in pregnancy.
        Case Rep Obstet Gynecol. 2020; 2020: 9283438
        • Padmanabhan A.
        • Connelly-Smith L.
        • Aqui N.
        • et al.
        Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue.
        J Clin Apheresis. 2019; 34: 171-354
        • van Rossum H.H.
        • de Kraa N.
        • Thomas M.
        • et al.
        Comparison of the direct antiglobulin test and the eluate technique for diagnosing haemolytic disease of the newborn.
        Pract Lab Med. 2015; 3: 17-22
        • Ercan E.
        • Ozg G.
        The accuracy of transcutaneous bilirubinometer measurements to identify the hyperbilirubinemia in outpatient newborn population.
        Clin Biochem. 2018; 55: 69-74
        • Bhutani V.K.
        • Stark A.R.
        • Lazzeroni L.C.
        Initial clinical testing evaluation and risk assessment for universal screening for hyperbilirubinemia screening group. Predischarge screening for severe neonatal hyperbilirubinemia identifies infants who need phototherapy.
        J Pediatr. 2013; 162: 477-482
        • Salih F.M.
        Can sunlight replace phototherapy units in the treatment of neonatal jaundice? An in vitro study.
        Photodermatol Photoimmunol Photomed. 2001; 17: 272-277
        • Slusher T.M.
        • Olusanya B.O.
        • Vreman H.J.
        • et al.
        Treatment of neonatal jaundice with filtered sunlight in Nigerian neonates: study protocol of a non-inferiority, randomized controlled trial.
        Trial. 2013; 14: 446
        • Wiener A.S.
        • Wexler I.B.
        • Gamrin E.
        Hemolytic disease of the fetus and the newborn infants with special reference to transfusion therapy and the use of the biological test for detecting Rh sensitivity.
        Am J Dis Child. 1944; 68: 317
        • Donel J.
        Bili blanket phototherapy.
        Int J Contemp Pediatr. 2019; 6: 2231-2234
        • Wallerstein H.
        Treatment of severe erythroblastosis fetalis by simultaneous removal and replacement of the blood of the newborn infant.
        Science. 1946; 103: 583
        • Jackson J.C.
        Adverse events associated with exchange transfusion in healthy and ill newborns.
        Pediatrics. 1997; 99: E7
        • Zwiers C.
        • Scheffer-Rath M.E.A.
        • Lopriore E.
        • et al.
        Immunoglobulin for alloimmune hemolytic disease in neonates.
        Cochrane Database Syst Rev. 2018; 3
        • Beken S.
        • Hirfanoglu I.
        • Turkyilmaz C.
        • et al.
        Intravenous immunoglobulin G treatment in ABO hemolytic disease of the newborn, is it myth or real?.
        Indian J Hematol Blood Transfus. 2014; 30: 12-15
        • Williams D.
        • Argaez C.
        Off-label use of intravenous immunoglobulin for hematological conditions: a review of clinical effectiveness . Canadian agency for drugs and technologies in health.
        (Available at:) (Accessed August 31, 2020)
        • Mundy C.A.
        • Bhatia J.
        Immunoglobulin transfusion in hemolytic disease of the newborn: place in therapy.
        Int J Clin Transfus Med. 2015; 3: 41-45
        • Baker J.M.
        • Campbell D.M.
        • Bhutani V.K.
        • et al.
        Rh sensitization in Canada is not obsolete.
        Paediatr Child Health. 2017; 22: 238-239
        • Pilgrim H.
        • Lloyd-Jones M.
        • Rees A.
        Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. 2009.
        in: NIHR Health Technology Assessment programme: Executive Summaries. NIHR Journals Library, Southampton (UK)2003 (Available at:) (Accessed August 31, 2020)
        • Zipursky A.
        • Bhutani B.
        Rhesus disease: a major public health problem.
        Lancet. 2015; 386: 651
        • MacKenzie I.Z.
        • Findlay J.
        • Thompson K.
        • et al.
        Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years.
        BJOG. 2006; 113: 839-843
        • Zipursky A.
        • Bhutani V.K.
        • Odame I.
        Rhesus disease: a global prevention strategy.
        Lancet Child Adolesc Health. 2018; 2: 536-542
        • Zipursky A.
        • Paul V.K.
        The global burden of Rh disease.
        Arch Dis Child Fetal Neonatal Ed. 2011; 96: F84-F85
        • Crowther C.A.
        • Keirse M.J.
        Anti-D administration in pregnancy for preventing rhesus alloimmunisation.
        Cochrane Database Syst Rev. 2000; 2: CD000020
        • Eldon K.
        Experience with ABO and Rh blood-grouping cards (Eldon cards).
        Br Med J. 1956; 2: 1218-1220
        • Bienek D.R.
        • Charlton D.G.
        Accuracy of user-friendly blood typing kits tested under simulated military field conditions.
        Mil Med. 2011; 176: 454-460
      4. Kleihauer (1974) Determination of Fetal Hemoglobin: Elution Technique, CRC Critical Reviews in Clinical Laboratory Sciences, 5:1, 50-52, DOI: 10.3109/10408367409107625.